Shannon M Parisotto, a vice president at Charles River Laboratories International, Inc. (CRL), sold 5,046 shares of company stock on August 5, 2026, in an open-market transaction totaling $1,327,098. The shares were sold at a price of $263.00 each, according to a Form 4 filed with the Securities and Exchange Commission on August 6, one day after the trade date.
The sale reduced Parisotto's direct holdings to 4,807 shares, representing a reduction of approximately 51% of the position held prior to the transaction. It is the only trade by Parisotto recorded in the database, and no other open-market sales by Charles River insiders have been filed in the preceding five months. The only other open-market insider transaction on CRL during that window was a purchase of 25 shares by VP Joseph W. Laplume on March 3, 2026, at a price of $174.54 per share — a transaction valued at $4,363.50.
On the day of the sale, CRL shares opened at $267.99, traded as low as $252.07, and closed at $260.72 on volume of roughly 1.78 million shares. The $263.00 execution price fell within the intraday range. Charles River Laboratories, a life sciences tools and services company, had a market capitalization of approximately $11.3 billion at the time of the trade.
Congressional trading records show that Representative Ro Khanna, a California Democrat, has been an active trader of CRL stock. Khanna disclosed a purchase of CRL shares in May 2026, valued at an estimated $1,001 at the midpoint of the disclosed range, and another purchase of the same estimated amount in March 2026. He also disclosed a sale of CRL in February 2026, also in the $1,001 midpoint range. Congressional disclosure amounts are midpoint estimates drawn from the bracketed ranges required by the STOCK Act. Khanna has disclosed multiple CRL transactions stretching back to 2025, including both purchases and sales.
Parisotto's Form 4 was filed on August 6, within the two-business-day window required by SEC rules for open-market transactions. The filing did not include footnotes indicating that the sale was executed under a pre-arranged 10b5-1 trading plan.